Literature DB >> 25669833

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Paul L Hess1, Sana M Al-Khatib2, Joo Y Han2, Rex Edwards2, Gust H Bardy2, J Thomas Bigger2, Alfred Buxton2, Riccardo Cappato2, Paul Dorian2, Al Hallstrom2, Alan H Kadish2, Peter J Kudenchuk2, Kerry L Lee2, Daniel B Mark2, Arthur J Moss2, Richard Steinman2, Lurdes Y T Inoue2, Gillian Sanders2.   

Abstract

BACKGROUND: The impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain. METHODS AND
RESULTS: Data from 5 major ICD trials were merged: the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), the Multicenter UnSustained Tachycardia Trial (MUSTT), the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Median age at enrollment was 62 (interquartile range 53-70) years. Compared with their younger counterparts, older patients had a greater burden of comorbid illness. In unadjusted exploratory analyses, ICD recipients were less likely to die than nonrecipients in all age groups: among patients aged <55 years: hazard ratio 0.48, 95% posterior credible interval 0.33 to 0.69; among patients aged 55 to 64 years: hazard ratio 0.69, 95% posterior credible interval 0.53 to 0.90; among patients aged 65 to 74 years: hazard ratio 0.67, 95% posterior credible interval, 0.53 to 0.85; and among patients aged ≥75 years: hazard ratio 0.54, 95% posterior credible interval 0.37 to 0.78. Sample sizes were limited among patients aged ≥75 years. In adjusted Bayesian-Weibull modeling, point estimates indicate ICD efficacy persists but is attenuated with increasing age. There was evidence of an interaction between age and ICD treatment on survival (two-sided posterior tail probability of no interaction <0.01). Using an adjusted Bayesian logistic regression model, there was no evidence of an interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability of no interaction 0.44).
CONCLUSIONS: In this analysis, the survival benefit of the ICD exists but is attenuated with increasing age. The latter finding may be because of the higher burden of comorbid illness, competing causes of death, or limited sample size of older patients. There was no evidence that age modifies the association between ICD treatment and rehospitalization.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  aging; defibrillators, implantable; meta-analysis

Mesh:

Year:  2015        PMID: 25669833      PMCID: PMC4408540          DOI: 10.1161/CIRCOUTCOMES.114.001306

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  31 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.

Authors:  David T Huang; Henry W Sesselberg; Scott McNitt; Katia Noyes; Mark L Andrews; W Jackson Hall; Andrew Dick; James P Daubert; Wojciech Zareba; Arthur J Moss
Journal:  J Cardiovasc Electrophysiol       Date:  2007-05-30

3.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

4.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2008-05-15       Impact factor: 29.690

5.  Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.

Authors:  Ilan Goldenberg; Arthur J Moss; W Jackson Hall; Scott McNitt; Wojciech Zareba; Mark L Andrews; David S Cannom
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

6.  Hospital readmission after transvenous cardioverter/defibrillator implantation; a single centre study.

Authors:  T Korte; W Jung; G Ostermann; C Wolpert; S Spehl; B Esmailzadeh; B Lüderitz
Journal:  Eur Heart J       Date:  2000-07       Impact factor: 29.983

7.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.

Authors:  A E Buxton; K L Lee; J D Fisher; M E Josephson; E N Prystowsky; G Hafley
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

8.  Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure.

Authors:  Adrian F Hernandez; Gregg C Fonarow; Bradley G Hammill; Sana M Al-Khatib; Clyde W Yancy; Christopher M O'Connor; Kevin A Schulman; Eric D Peterson; Lesley H Curtis
Journal:  Circ Heart Fail       Date:  2009-12-15       Impact factor: 8.790

9.  Survival after implantable cardioverter-defibrillator implantation in the elderly.

Authors:  Derek Yung; David Birnie; Paul Dorian; Jeffrey S Healey; Christopher S Simpson; Eugene Crystal; Andrew D Krahn; Yaariv Khaykin; Douglas Cameron; Zhongliang Chen; Douglas S Lee
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690

10.  Implantable cardioverter-defibrillator prescription in the elderly.

Authors:  Andrew E Epstein; G Neal Kay; Vance J Plumb; H Thomas McElderry; Harish Doppalapudi; Takumi Yamada; Jeff Shafiroff; Zaffer A Syed; Sergio Shkurovich
Journal:  Heart Rhythm       Date:  2009-04-10       Impact factor: 6.343

View more
  22 in total

1.  Capsule Commentary on Al-Khatib et al., Future Research Prioritization: Implantable Cardioverter Defibrillator Therapy in Older Patients.

Authors:  Nicoletta Riva; Christian Borg Xuereb
Journal:  J Gen Intern Med       Date:  2015-12       Impact factor: 5.128

2.  Let's talk chronic heart failure.

Authors:  Michael Slawnych; Nakul Sharma; Debra Isaac; Jessica Simon
Journal:  CMAJ       Date:  2015-08-11       Impact factor: 8.262

Review 3.  Contemporary Management of Heart Failure in the Elderly.

Authors:  Joanna Osmanska; Pardeep S Jhund
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

Review 4.  [ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection].

Authors:  J Neuzner; R Gradaus
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-06-04

Review 5.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

6.  Determinants of outcomes following outpatient placement of implantable cardioverter defibrillators in a Medicare Advantage population.

Authors:  Teresa L Rogstad; Adam C Powell; Yongjia Song; Tristan Cordier; Stephen E Price; James W Long; Uday U Deshmukh; Jeffrey D Simmons
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

Review 7.  Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence.

Authors:  Harsha V Ganga; Abhishek Maan; E Kevin Heist
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 8.  [ICD in elderly patients].

Authors:  Carsten W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-03

Review 9.  Arrhythmias in Patients ≥80 Years of Age: Pathophysiology, Management, and Outcomes.

Authors:  Anne B Curtis; Roshan Karki; Alexander Hattoum; Umesh C Sharma
Journal:  J Am Coll Cardiol       Date:  2018-05-08       Impact factor: 24.094

Review 10.  New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.

Authors:  Daniel J Friedman; Sana M Al-Khatib; Emily P Zeitler; JooYoon Han; Gust H Bardy; Jeanne E Poole; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Richard Steinman; Paul Dorian; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders
Journal:  Am Heart J       Date:  2017-06-09       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.